Printer Friendly

Synspira Therapeutics signs contract with Cystic Fibrosis Foundation.

M2 PHARMA-February 13, 2020-Synspira Therapeutics signs contract with Cystic Fibrosis Foundation

(C)2020 M2 COMMUNICATIONS

Synspira Therapeutics Inc, a clinical-stage biopharmaceutical company that says that it is dedicated to improving the lives of people with cystic fibrosis and other rare diseases, announced on Wednesday that it has signed a contract with Cystic Fibrosis Foundation.

The agreement has been signed to support the development of SNSP003, Synspira's orally delivered non-porcine enzyme replacement therapy intended to treat Malabsorption Syndromes.

The product is a rationally designed treatment including a precise combination of three purified enzymes (lipase, protease and amylase). It is claimed to have the potential to improve clinical results and also to dramatically decrease treatment burden by improving dosing convenience and offering a formulation for paediatric and adult patients unable to swallow capsules.

Synspira's oral enzyme delivery technology is expected to provide a significant advancement over current porcine-based pancreatic enzyme replacement therapies (PERT).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 13, 2020
Words:162
Previous Article:Elanco to divest EEA and UK rights to Drontal and Profender.
Next Article:Sirtex Medical collaborates with MIM Software.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters